1 result for "Actinium Pharmaceuticals, Inc."
Add this URL to any RSS reader. Updated daily.
Actinium-225 Anti-CD45 Antibody Composition Patent Granted
The USPTO granted patent US12605472B2 to Actinium Pharmaceuticals, Inc. on April 21, 2026, covering compositions and methods for treating hematological diseases using actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose. The patent claims 23 compositions and methods of use for treating hemoglobinopathies and hematological malignancies.
Routine
Notice
Intellectual Property
Get alerts for "Actinium Pharmaceuticals, Inc."
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Browse Categories
Agriculture & Food Safety
73
AI Regulation
3
Banking & Finance
414
Consumer Protection
89
Courts & Legal
411
Data Privacy & Cybersecurity
90
Defense & National Security
53
Education
55
Energy
100
Environment
152
Gaming
2
Government & Legislation
431
Healthcare
15
Healthcare & Life Sciences
375
Immigration
10
Insurance
76
Labor & Employment
138
Pharma & Drug Safety
21
Professional Licensing
8
Real Estate & Housing
78
Securities & Markets
154
Tax
78
Telecom & Technology
47
Trade & Sanctions
141
Transportation
91
Get alerts for "Actinium Pharmaceuticals, Inc."
We'll email you when new changes match "Actinium Pharmaceuticals, Inc.".
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.
You're subscribed!